CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Infliximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00725452
NCT00725452N/ACompleted
CompareCT.gov

Real Life Treatment Regimen of Remicade (Infliximab) in Austria, Monitored Over 5 Years in Plaque Psoriasis Therapy

Merck Sharp & Dohme LLC·observational·Posted Jul 30, 2008·Updated Jul 28, 2015

In Brief

An observational study evaluating Infliximab for Psoriasis. Completed, enrolled 26 participants.

Detailed Summary

Prospective, open-label-, 1-arm, multicenter observational study to determine the dose and interval of Infliximab infusions for subjects with plaque psoriasis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsCentocor, Inc.

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2008
Enrollment StartOct 1, 2006
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.9 years ago

Interventions

Infliximabbiological

Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.